Pioneering ultra-deep plasma proteomics and quantitative mass spectrometry to accelerate clinical biomarker discovery and future SaMD licensing pipelines

TAIPEI, Taiwan — July 16, 2026 — At the prestigious BIO Asia-Taiwan 2026 (NSTC Pavilion, Booth N602), MarkerX, a pioneering leader in AI-driven proteomics, officially unveiled its next-generation AI-Driven Mass Spec Proteomics Platform, delivering an ultra-deep proteomics analysis service engineered to overcome the long-standing challenges of clinical translational research.

By utilizing a proprietary protein enrichment technology, the platform successfully bypasses high-abundance protein interference in blood plasma. Recent research studies demonstrate that this technology identifies over 1,400 proteins in enriched plasma, with more than 800 proteins showing highly stable expression (CV < 25%). This represents a thousand-fold leap in sensitivity compared to conventional methods. Having been selected earlier this year for the elite "Mayo Clinic and ASU Alliance for Health Care Accelerator," MarkerX’s technology continues to garner global validation for its translational and software development capabilities.

Why Choose MarkerX? Four Core Technological Breakthroughs

Designed to address critical bottlenecks in biopharma R&D and clinical trials, the MarkerX platform utilizes state-of-the-art quantitative mass spectrometry (LC-MS/MS) to deliver deep molecular insights through four proprietary innovations:

• Intelligent Background De-noising (Plasma Background Suppression): Utilizing a proprietary protein enrichment technology, the platform selectively captures low-abundance target proteins. Validated by Gene Ontology (GO) enrichment analysis, the workflow effectively suppresses background noise from high-abundance hydrolases, complements, and coagulation factors, unlocking critical low-abundance protein signals linked to cell binding and key signaling pathways.
• Precision Molecular Stratification (Dynamic Patient Cohort Tracking): Supported by recent clinical research datasets, the platform successfully screens and identifies statistically significant differentially expressed specific biomarkers (ANOVA $P < 0.05$) in cohorts spanning neurodegenerative disease patients and age-matched healthy controls—demonstrating immense potential for clinical disease stratification and longitudinal progression monitoring.
• Decoding Challenging FFPE Tissue Specimens: MarkerX's proprietary FFPE proteomics analysis workflow successfully recovers high-fidelity, complete molecular signals from highly degraded, long-stored formalin-fixed paraffin-embedded (FFPE) pathology blocks. This unlocks invaluable retrospective clinical data for oncological research and phosphoproteomics analysis.
• Digital Molecular Weight Measurement (Bypassing IHC Limitations): Combining Laser Capture Microdissection (LCM) with high-resolution tandem mass spectrometry, this workflow replaces traditional immunohistochemistry (IHC) visual scoring, antibody non-specific binding, and false-negative limitations with objective, data-driven mass spec molecular phenotyping.

Integrated Platform: Advanced Protein Enrichment Meets MarkerX AI

The platform integrates a novel protein enrichment method—which solves the proteomics "needle-in-a-haystack" bottleneck—with MarkerX's advanced proprietary machine-learning algorithms that translate raw multi-omics datasets into actionable clinical insights.

"This technological breakthrough redefines the boundaries of clinical plasma proteomics," said Jerry Huang, CEO of MarkerX. "By integrating an advanced protein enrichment technology with our AI platform, we do not only decipher disease codes within massive datasets but also turn this into proprietary assets to continuously iterate our core algorithms and data walls."

When asked about the company's long-term commercial roadmap, Huang emphasized: "Our current contract research services represent the vital first step of our data flywheel. Ultimately, our vision is to transform these proprietary molecular profiles into high-margin, globally scalable, and decentralized Software-as-a-Medical-Device (SaMD) cloud licenses. This will empower medical centers worldwide with real-time, clinically actionable diagnostics, achieving true asset-light expansion."

A Global Launchpad via the Mayo Clinic Accelerator

MarkerX's selection into "The Mayo Clinic and ASU Alliance for Health Care Accelerator" provides a prestigious global clinical validation. In the landscape of precision medicine, proteomics is recognized as a closer reflection of real-time pathology than genomics, and MarkerX is poised to lead this transition.

During BIO Asia-Taiwan 2026, MarkerX is actively demonstrating its capabilities as a premier biotech contract research partner, offering multi-module workflows from customized phosphoproteomics to complex multi-omics data interpretation for global pharmaceutical companies and clinical investigators.

Visit Booth N602 at BIO Asia-Taiwan 2026

MarkerX warmly invites academic experts, drug development executives, and clinical PIs to visit Booth N602 (National Science and Technology Council Pavilion) from July 16 to July 19.

We are releasing a limited 10 slots of exclusive, customized promotional consultations onsite! Visitors can also download our latest technical whitepapers to explore how quantitative mass spectrometry can transform their clinical pipelines.

About MarkerX 

MarkerX is a pioneer in AI-driven mass spectrometry proteomics. The company offers one-stop solutions for clinical biomarker discovery and translational medical research. Using its rapidly growing clinical data library as a foundation, MarkerX is actively developing its future pipeline for international Software-as-a-Medical-Device (SaMD) licensing, aiming to accelerate biomarker development for oncology and neurodegenerative diseases worldwide.

【Media Contact & Resources】

 Debby Chen | Industry & Market Analyst, Office of the CEO

 02-7730-2526 | support@marker-x.com | https://marker-x.com/

 Download Press Kit & Media Assets